SEC Tracker
Get the app

Quince Therapeutics IRLA

Quince Therapeutics Q2 FY24: net loss $27.7M; diluted EPS −$0.64

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Quince Therapeutics reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$27.7MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.64No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$7.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$8.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Quince Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Veru VERU public float $64M, Mar 31, 2025, over 18 months old
  2. Lifevantage LFVN public float $64M, Dec 31, 2025
  3. Whitehawk Therapeutics WHWK public float $65M, Jun 30, 2025
  4. Medicinova MNOV public float $62M, Jun 30, 2025
  5. Corbus Pharmaceuticals Holdings CRBP public float $68M, Jun 30, 2025